Focused On-demand Library for Proteasome subunit beta type-9

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P28065

UPID:

PSB9_HUMAN

Alternative names:

Low molecular mass protein 2; Macropain chain 7; Multicatalytic endopeptidase complex chain 7; Proteasome chain 7; Proteasome subunit beta-1i; Really interesting new gene 12 protein

Alternative UPACC:

P28065; B0V0T1; Q16523; Q5JNW4

Background:

The Proteasome subunit beta type-9, known by alternative names such as Low molecular mass protein 2 and Really interesting new gene 12 protein, plays a crucial role in the proteasome complex. This complex is essential for cleaving peptides, a process vital for antigen processing and generating class I binding peptides. The unique ability of this subunit to replace PSMB6 with PSMB9 enhances the immunoproteasome's capacity to cleave peptides after hydrophobic and basic residues.

Therapeutic significance:

Proteasome subunit beta type-9 is implicated in Proteasome-associated autoinflammatory syndrome 3, a disorder marked by fever, dermatitis, and immune dysregulation. Understanding the role of this protein could open doors to potential therapeutic strategies for treating autoinflammatory disorders and improving immune system regulation.